# Babynostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/babynostics

- Industry: Healthcare
- Headquarters: Singapore, Singapore
- Website: www.babynostics.net
- Total disclosed funding: $1.7M
- Latest round: Series A (Jan 19, 2021)
- Investors on record: 2

## About

Babynostics specializes in innovative healthcare solutions for neonatal diagnostics, offering advanced tools that enhance testing accuracy and speed in newborns, thus addressing critical health issues effectively.Babynostics is a healthcare company focused on neonatal diagnostics. Founded in Singapore, the company has developed advanced diagnostic tools aimed at improving newborn health outcomes. Notably, Babynostics raised USD 1.70 mn in Series A funding on January 19, 2021, which has contributed to its current valuation of USD 16.79 mn. The funding was sourced from notable investors including Sprim Ventures and Tikehau Investment Management.Babynostics focuses on innovative healthcare solutions designed specifically for neonatal diagnostics. The company's flagship offerings include advanced diagnostic tools aimed at improving the accuracy and speed of testing in newborns, addressing critical health concerns such as metabolic disorders and infections. These products integrate technology to facilitate early detection, ultimately enhancing patient outcomes in various clinical settings. Babynostics serves a diverse clientele that includes hospitals, pediatric clinics, and healthcare providers across Europe and North America.Babynostics generated USD 0 mn in revenue for the most recent year, 2021. The company operates primarily through direct sales of its diagnostic products to healthcare institutions and medical professionals, utilizing a B2B transaction structure. The revenue model is supported by the rising demand for reliable neonatal diagnostic solutions, reflecting the value provided in clinical applications.Babynostics plans to leverage its recent funding to expand its product line with new diagnostic tools specifically designed for emerging neonatal health challenges. The company aims to enter additional markets in Asia and North America by the end of 2023. The Series A funding, amounting to USD 1.70 mn, will support these initiatives, facilitating research and development efforts to enhance product offerings and operational capabilities.

## Funding rounds

- Series A, Jan 19, 2021, $1.7M — Tikehau Capital, Sprim Ventures

## Investors

- Tikehau Capital — Series A
- Sprim Ventures (https://capitalatlas.ai/funds/sprim-ventures) — Series A